Plasma vascular endothelial growth factor and its receptor Flt-1 in patients with hyperlipidemia and atherosclerosis and the effects of Fluvastatin or Fenofibrate
Plasma vascular endothelial growth factor and its receptor Flt-1 in patients with hyperlipidemia and atherosclerosis and the effects of Fluvastatin or Fenofibrate
复制标题
DOI：
10.1016/s0002-9149(01)01486-2
复制
发表时间：
2001-05-15
影响因子：
2.8
通讯作者：
Lip, GYP
中科院分区：
文献类型：
--
作者：
Blann, AD;Belgore, FM;Lip, GYP
血管内皮细胞生长因子 (VEGF) 的增加可能在心血管病理生理学中很重要（可能与血管生成和侧支血管发育有关），并通过 Flt-1 等受体结合靶内皮。我们假设，与对照组相比，动脉粥样硬化患者和其他高脂血症患者的血浆 VEGF 和 Flt-1 水平会升高，而经过 3 个月的降脂治疗后，这些因素会减少。研究对象为 20 名无并发症高脂血症但无动脉粥样硬化的患者、20 名高脂血症伴明确动脉粥样硬化的患者以及 40 名匹配的对照者。患者组的血浆 VEGF 高于健康对照组 (p
Increased vascular endothelial cell growth factor (VEGF) may be important in cardiovascular pathophysiology (perhaps relating to angiogenesis and collateral vessel development) and binds target endothelium via receptors such as Flt-1. We hypothesized that there would be increased levels of plasma VEGF and Flt-1 in patients with atherosclerosis and others with hyperlipidemia compared with controls, and a reduction in these factors with 3 months of lipid-lowering therapy. Twenty patients with uncomplicated hyperlipidemia but no atherosclerosis, 20 patients with hyperlipidemia plus clear atherosclerosis, and 40 matched controls were studied. Plasma VEGF was higher in patient groups than in healthy controls (p